IDEFIRIX Market Summary

Key Factors Driving IDEFIRIX Growth

1. High unmet need among highly sensitized kidney-transplant patients: IDEFIRIX is designed for highly sensitized adults who have a positive crossmatch against an available deceased-donor kidney and therefore have very limited access to compatible organs. Imlifidase rapidly cleaves circulating IgG, including donor-specific antibodies, creating a temporary window in which an otherwise HLA-incompatible transplant can proceed. This addresses a particularly difficult subgroup of the kidney-transplant population.

2. Strong clinical validation and long-term evidence: Phase II studies demonstrated that imlifidase could convert a positive crossmatch to negative within 24 hours, enabling transplantation in highly sensitized patients. Longer-term follow-up has also reported 84% allograft survival at 3 years, with a mean eGFR of approximately 55 mL/min/1.73 m². Although antibody-mediated rejection remains an important management issue, these data provide an expanding evidence base supporting clinical adoption.

3. Rapid commercial growth in Europe: Hansa Biopharma reported IDEFIRIX product sales of SEK 204.7 million in 2025, representing a 46% increase from SEK 140.1 million in 2024. Q4 2025 sales were particularly strong at SEK 61.1 million, up 139% year over year. Hansa attributed the full-year growth to increased adoption across major European markets.

4. Expansion of reimbursement and geographic access: Commercial growth is being supported by expanding reimbursement. Hansa reported that IDEFIRIX had reimbursement coverage in 24 European countries by the end of 2025, compared with 18 markets reported for 2024. The company also highlighted new national guidelines in Spain and Belgium, alongside increasing adoption and market-access expansion. Broader reimbursement lowers an important barrier to utilization because IDEFIRIX is intended for a relatively specialized transplant population.

5. Potential expansion into the U.S. market: A major future growth catalyst is the potential U.S. launch. Hansa reported positive topline results from the pivotal Phase III ConfIdeS trial in 2025, with the primary endpoint met at p<0.0001. In December 2025, the company submitted a Biologics License Application (BLA) to the FDA seeking approval for desensitization of highly sensitized adults undergoing deceased-donor kidney transplantation. A U.S. approval would provide access to a substantially larger transplant market than IDEFIRIX currently addresses commercially.

IDEFIRIX Recent Developments

In July 2026, Hansa Biopharma closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA.

Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by the European Commission for the desensitisation treatment of highly sensitised adult kidney transplant patients with a positive crossmatch test against an available deceased donor.

Under the agreement, Hansa has granted SERB an exclusive license for the development and commercialisation of Idefirix in solid organ transplantation in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and the MENA (Middle East and North Africa) region.

“IDEFIRIX Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of IDEFIRIX for approved indication like Renal transplant rejection; as well as potential indication like Anti-glomerular basement membrane disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Crigler-Najjar syndrome, Guillain-Barre syndrome, Thrombotic thrombocytopenic purpura in the 7MM. A detailed picture of IDEFIRIX’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the IDEFIRIX for approved and potential indications. The IDEFIRIX market report provides insights about IDEFIRIX’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IDEFIRIX performance, future market assessments inclusive of the IDEFIRIX market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IDEFIRIX sales forecasts, along with factors driving its market.

IDEFIRIX Drug Summary

IDEFIRIX is a recombinant IgG-degrading enzyme derived from Streptococcus pyogenes and is used as an immunomodulatory therapy to enable kidney transplantation in highly sensitized adult patients who are unlikely to receive a compatible organ through the available kidney-allocation system. Imlifidase is an IgG-specific cysteine protease that rapidly cleaves circulating immunoglobulin G (IgG), including donor-specific anti-HLA antibodies, thereby temporarily reducing antibody-mediated barriers to transplantation and converting a positive crossmatch to a negative one in appropriately selected patients. IDEFIRIX is administered as a single intravenous infusion, with transplantation generally performed after confirmation that the patient's donor-specific antibodies have been sufficiently reduced. Because IgG levels and anti-donor antibodies can subsequently rebound, the treatment provides a limited window of immunological compatibility rather than permanent desensitization. IDEFIRIX is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor, subject to specific clinical criteria. Key safety considerations include infections, infusion-related reactions, and the potential for antibody rebound and antibody-mediated rejection; consequently, patients require intensive post-transplant monitoring and conventional immunosuppression. IDEFIRIX was developed by Hansa Biopharma and represents a targeted enzymatic approach to overcoming pre-existing anti-donor IgG antibodies in highly sensitized kidney transplant recipients. The report provides IDEFIRIX’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IDEFIRIX Market Report

The report provides insights into:

• A comprehensive product overview including the IDEFIRIX MoA, description, dosage and administration, research and development activities in approved indications like Renal transplant rejection; as well as potential indication like Anti-glomerular basement membrane disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Crigler-Najjar syndrome, Guillain-Barre syndrome, Thrombotic thrombocytopenic purpura.
• Elaborated details on IDEFIRIX regulatory milestones and other development activities have been provided in IDEFIRIX market report.
• The report also highlights IDEFIRIX‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The IDEFIRIX market report also covers the patents information, generic entry and impact on cost cut.
• The IDEFIRIX market report contains current and forecasted IDEFIRIX sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IDEFIRIX market report also features the SWOT analysis with analyst views for IDEFIRIX in approved and potential indications.

Methodology

The IDEFIRIX market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IDEFIRIX Analytical Perspective by DelveInsight

• In-depth IDEFIRIX Market Assessment

This IDEFIRIX sales market forecast report provides a detailed market assessment of IDEFIRIX for approved indication like Renal transplant rejection; as well as potential indication like Anti-glomerular basement membrane disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Crigler-Najjar syndrome, Guillain-Barre syndrome, Thrombotic thrombocytopenic purpura in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IDEFIRIX sales data uptil 2034.

• IDEFIRIX Clinical Assessment

The IDEFIRIX market report provides the clinical trials information of IDEFIRIX for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IDEFIRIX Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IDEFIRIX Market Potential & Revenue Forecast

• Projected market size for the IDEFIRIX and its key indications
• Estimated IDEFIRIX sales potential (IDEFIRIX peak sales forecasts)
• IDEFIRIX Pricing strategies and reimbursement landscape

IDEFIRIX Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IDEFIRIX Market positioning compared to existing treatments
• IDEFIRIX Strengths & weaknesses relative to competitors

IDEFIRIX Regulatory & Commercial Milestones

• IDEFIRIX Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IDEFIRIX Clinical Differentiation

• IDEFIRIX Efficacy & safety advantages over existing drugs
• IDEFIRIX Unique selling points

IDEFIRIX Market Report Highlights

• In the coming years, the IDEFIRIX market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IDEFIRIX companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IDEFIRIX’s dominance.
• Other emerging products for Renal transplant rejection; as well as potential indication like Anti-glomerular basement membrane disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Crigler-Najjar syndrome, Guillain-Barre syndrome, Thrombotic thrombocytopenic purpura are expected to give tough market competition to IDEFIRIX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IDEFIRIX in approved and potential indications.
• Analyse IDEFIRIX cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IDEFIRIX sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IDEFIRIX in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IDEFIRIX? How strong is IDEFIRIX’s clinical and commercial performance?
• What is IDEFIRIX’s clinical trial status in each individual indications such as Renal transplant rejection; as well as potential indication like Anti-glomerular basement membrane disease, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Crigler-Najjar syndrome, Guillain-Barre syndrome, Thrombotic thrombocytopenic purpura and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IDEFIRIX Manufacturers?
• What are the key designations that have been granted to IDEFIRIX for approved and potential indications? How are they going to impact IDEFIRIX’s penetration in various geographies?
• What is the current and forecasted IDEFIRIX market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IDEFIRIX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IDEFIRIX for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is IDEFIRIX? What is the duration of therapy and what are the geographical variations in cost per patient?